Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc32381264    free
PDF from PMC    free
html from PMC    free
PDF vom PMID32381264  :  Publisher
PDF vom PMID32381264

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis #MMPMID32381264
  • Klok FA; Kruip MJHA; van der Meer NJM; Arbous MS; Gommers D; Kant KM; Kaptein FHJ; van Paassen J; Stals MAM; Huisman MV; Endeman H
  • Thromb Res 2020[Jul]; 191 (ä): 148-150 PMID32381264show ga
  • INTRODUCTION: We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses. METHODS: We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first. RESULTS: We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8). CONCLUSION: In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia.
  • |Acute Disease[MESH]
  • |Anticoagulants/therapeutic use[MESH]
  • |Arterial Occlusive Diseases/*epidemiology/etiology[MESH]
  • |Brain Ischemia/epidemiology/etiology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus Infections/*complications[MESH]
  • |Critical Illness[MESH]
  • |Embolism/epidemiology/etiology[MESH]
  • |Female[MESH]
  • |Follow-Up Studies[MESH]
  • |Hospitals, Teaching/statistics & numerical data[MESH]
  • |Hospitals, University/statistics & numerical data[MESH]
  • |Humans[MESH]
  • |Incidence[MESH]
  • |Male[MESH]
  • |Middle Aged[MESH]
  • |Myocardial Infarction/epidemiology/etiology[MESH]
  • |Netherlands/epidemiology[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/*complications[MESH]
  • |Pulmonary Embolism/*epidemiology/etiology[MESH]
  • |Thrombophilia/drug therapy/*etiology[MESH]
  • |Venous Thrombosis/*epidemiology/etiology[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    148 ä.191 2020